The global market for Alpha-emitter Radioligand Therapy (ART) is at the forefront of precision oncology, driven by its ability to deliver highly potent, targeted radiation (alpha particles) directly to cancer cells while minimizing damage to surrounding healthy tissue. ART utilizes radioisotopes linked to targeting molecules (ligands) that bind specifically to tumor-associated antigen... https://in.linkedin.com/company/data-bridge-market-research